Scholarlink

Purpose <p>Chemerin, an adipokine involved in immune regulation and inflammation, has been implicated in the pathogenesis of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). However, existing studies have reported inconsistent findings regarding its diagnostic value. This meta-analysis aimed to clarify the association between blood chemerin levels and IBD.</p> Methods <p>A systematic search was conducted in PubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure (CNKI) up to February 10, 2024. Observational studies comparing blood chemerin levels between IBD patients and healthy controls, or between active and non-active IBD, were included. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a random-effects model by incorporating the possible influence of the heterogeneity.</p> Results <p>Ten case-control studies with 18 datasets involving 799 CD patients, 520 UC patients, 609 healthy controls, were included. Compared with healthy controls, IBD patients had significantly higher blood chemerin levels (SMD: 0.61, 95% CI: 0.46–0.76, <i>p</i> &lt; 0.001; I² = 48%). This association remained consistent across subgroups by disease type, study quality score, study region, and BMI matching (<i>p</i> for subgroup difference all &gt; 0.05). Furthermore, chemerin levels were higher in active versus non-active IBD patients (SMD: 0.36, 95% CI: 0.15–0.57, <i>p</i> &lt; 0.001; I² = 38%), with robust findings across subgroup and sensitivity analyses. No significant publication bias was detected.</p> Conclusions <p>Elevated blood chemerin levels are associated with both the presence and activity of IBD, supporting its potential role as a non-invasive biomarker for disease diagnosis and monitoring.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chemerin as a biomarker of inflammatory bowel diseases: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Zhi Tian,
  • Qun Xiang,
  • Meichun Long,
  • Jiangtao Liao,
  • Fang Wang,
  • Xuefeng Li

摘要

Purpose

Chemerin, an adipokine involved in immune regulation and inflammation, has been implicated in the pathogenesis of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). However, existing studies have reported inconsistent findings regarding its diagnostic value. This meta-analysis aimed to clarify the association between blood chemerin levels and IBD.

Methods

A systematic search was conducted in PubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure (CNKI) up to February 10, 2024. Observational studies comparing blood chemerin levels between IBD patients and healthy controls, or between active and non-active IBD, were included. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a random-effects model by incorporating the possible influence of the heterogeneity.

Results

Ten case-control studies with 18 datasets involving 799 CD patients, 520 UC patients, 609 healthy controls, were included. Compared with healthy controls, IBD patients had significantly higher blood chemerin levels (SMD: 0.61, 95% CI: 0.46–0.76, p < 0.001; I² = 48%). This association remained consistent across subgroups by disease type, study quality score, study region, and BMI matching (p for subgroup difference all > 0.05). Furthermore, chemerin levels were higher in active versus non-active IBD patients (SMD: 0.36, 95% CI: 0.15–0.57, p < 0.001; I² = 38%), with robust findings across subgroup and sensitivity analyses. No significant publication bias was detected.

Conclusions

Elevated blood chemerin levels are associated with both the presence and activity of IBD, supporting its potential role as a non-invasive biomarker for disease diagnosis and monitoring.